PirainoB., BernardiniJ., SorkinM.The influence of peritoneal catheter exit site infections on peritonitis, tunnel infections, and catheter loss in patients on continuous ambulatory peritoneal dialysis.Am J Kidney Dis1986; 6: 436–40.
2.
GuptaB., BernardiniJ., PirainoB.Peritonitis associated with exit site and tunnel infections.Am J Kidney Dis1996; 28: 415–19.
3.
LuzarM.A., ColesG.A., FallerB., SlingeneyerA., Dah DahG., BriatC.Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis.N Engl J Med1990; 322: 505–9.
4.
LyeW.C., LeongS.O., van der StraatenJ., LeeE.J.C.Staphylococcus aureus C APD-related infections are associated with nasal carriage.Adv Perit Dial1994; 10: 163–5.
5.
SwartzR., MessanaJ., StarmannB., WeberM., ReynoldsJ.Preventing Staphylococcus aureus infection during chronic peritoneal dialysis.J Am Soc of Nephrol1991; 2: 1085–91.
6.
ZimmermanS.W., AhrensE., JohnsonC.A., CraigW., LeggettJ., O'BrienM.Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections.Am J Kidney Dis1991; 18: 225–31.
7.
BernardiniJ., PirainoB., HolleyJ., JohnstonJ.R., LutesR.A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.Am J Kidney Dis1996; 27: 695–700.
8.
The Mupirocin Study Group.Nasal mupirocin prevents Staphylococcus aureus exit site infection during peritoneal dialysis.J Am Soc Nephrol1996; 11: 2403–8.
9.
DaveyP., CraigA., HauC., MalekM.Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized placebo-controlled trial.J Antimicrob Chemother1999; 43: 105–12.
10.
AmatoD., VenturaM., MirandaG., LeanosB., AlcantaraG., HurtadoM.Staphylococcal peritonitis in continuous ambulatory peritoneal dialysis: colonization with identical strains at exit site, nose, and hands.Am J Kidney Dis2001; 37: 43–8.
11.
VychytilA., LorenzM., SchneiderB., HorlW., Haag-WeberM.New strategies to prevent Staphylococcus aureus infection in peritoneal dialysis patients.J Am Soc Nephrol1998; 9: 669–76.
12.
HerwaldtL.A., BoykenL.D., CoffmanS., Hochstetler, FlaniganM.J.Sources of Staphylococcus aureus for patients on continuous ambulatory peritoneal dialysis.Perit Dial Int2003; 23: 237–41.
13.
PirainoB., BernardiniJ., FlorioT., FriedL.Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients.Perit Dial Int2003; 23: 456–9.
14.
BernardiniJ., BenderF., FlorioT., SloandJ., PalmMontalbanoL., FriedL.Randomized double blinded trial of peritoneal dialysis exit site mupirocin 2% versus gentamicin sulfate 0.1% cream.J Am Soc Nephrol2005; 16: 539–45.
Perez-Font anM., RosalesM., Rodriguez-CarmonaA., Garcia-FalconT., ValdesF.Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients on peritoneal dialysis.Am J Kidney Dis2002; 39: 337–41.
17.
AnnigeriR., Conly, VasS.I., DedierH., PrakashanK.P., BargmanJ.M.Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.Per it Dial Int2001; 21: 554–9.
18.
DanguilanR.A., EvangelistaL.P., AbrenicaM.S., RondillaS.M.Comparative study of mupirocin and sodium fucidate in the prophylaxis of exit-site infections in CAPD patients.Perit Dial Int2003; 23: 593–5.
19.
CavdarC., ZeybelM., AtayT., SifilA., SanlidagC., GulayZ.The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis—first 6 months’ experience.Adv Perit Dial2004; 20: 62–6.
20.
SessoR., ParisioK., DalboniA., RabeloT., BarbosaD., CendorogloM.Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol1994; 41: 370–6.
21.
LuzarM.A., BrownC.B., BalfD., HillL., IssadB., MonnierB.Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicentered trial.Perit Dial Int1990; 10: 25–9.
22.
WaiteN.M., WebsterN., LaurelM., JohnsonM., FongI.W.The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis related infections.Am J Kidney Dis1997; 29: 763–8.
23.
TacconelliE., CarmeliY., AizerA., FerreiraG., ForemanM.G., D'AgataE.Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis.Clin Infect Dis2003; 37: 1629–38.
24.
StrippoliG.F.M., TongF.M., JohnsonA.D., SchenaF., CraigJ.Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials.Am J Kidney Dis2004; 44: 591–603.
25.
ChuK.H., ChoyW.Y., CheungC.C.W., FungK.S., TangH.L., LeeW.A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections.Perit Dial Int2008; 28: 505–8.
